Dok (for downstream of tyrosine kinases) proteins are a newly identified family of docking molecules that are characterized by the presence of an amino-terminal pleckstrin homology (PH) domain, a central putative phosphotyrosine-binding (PTB) domain and numerous potential sites of tyrosine phosphorylation [1-6]. Here, we explore the potential role of the Dok family member Dok-R (also known as p56 Dok2 or FRIP) in signaling pathways mediated by the epidermal growth factor (EGF) receptor. An intact PTB domain in Dok-R was critical for its association with two PTB-binding consensus sites on the EGF receptor and the PH domain further contributed to stable in vivo binding and tyrosine phosphorylation of Dok-R. Multiple sites on Dok-R were tyrosine-phosphorylated following EGF stimulation; phosphorylated Tyr276 and Tyr304 are proposed to dock the tandem Src homology 2 (SH2) domains of the p21 Ras GTPase-activating protein rasGAP and Tyr351 mediates an association with the SH2 domain of the adapter protein Nck. Interestingly, we have found that Dok-R could attenuate EGFstimulated mitogen-activated protein (MAP) kinase activation independently of its association with rasGAP. Together, these results suggest that Dok-R has an important role downstream of growth factor receptors as a potential negative regulator of signal transduction. 
Results and discussion
Tyrosine phosphorylation of Dok in response to EGF stimulation has previously been reported [7, 8] . Given the similar expression profiles of Dok and Dok-R, we reasoned that Dok-R might also function in EGF-mediated signaling pathways. To test this, we used the COS1 cell line, which expresses high levels of EGF receptor [9] and does not contain endogenous Dok-R (data not shown); there is thus no interference with the analysis of signaling mediated by exogenously expressed forms. In COS1 cells transiently expressing full-length Dok-R, we found that EGF stimulation resulted in complex formation between the EGF receptor and Dok-R and in tyrosine phosphorylation of both proteins (see Supplementary material). A region of Dok-R similar to the PTB domain of insulin receptor substrate-1 (IRS-1) has previously been shown to mediate binding of Dok-R to the phosphorylated Tek/Tie2 receptor [3] . As the sequence similarity between PTB domains is limited and as the Tek/Tie2 receptor does not contain the consensus binding site for PTB domains, we wanted to ascertain whether this region of Dok-R represented a true PTB domain. Purified fusion proteins of glutathione-S-transferase (GST) with the putative Dok-R PTB domain (GST-PTB) or a mutant domain lacking two conserved arginine residues (GST-PTB*) [10, 11] were used to precipitate the EGF receptor from lysates of nontransfected unstimulated or EGF-stimulated COS1 cells. Figure 1a shows that the PTB domain of Dok-R could precipitate the EGF receptor following EGF stimulation and that the PTB* domain could not.
To determine which tyrosines of the EGF receptor could mediate the interaction with Dok-R, we designed a series of synthetic peptides corresponding to the sequences surrounding the autophosphorylation sites of the EGF receptor ( Figure 1b ) [12] and mixed them in vitro with purified GST-PTB fusion proteins. The GST-PTB domain of Dok-R could be precipitated by phosphopeptides representing Tyr1086 (pY1086) and Tyr1148 (pY1148) but not by the unphosphorylated counterparts (Y1086 and Y1148; Figure 1c ). In contrast, neither GST-PTB* nor GST alone could be precipitated by either of these phosphopeptides and the PTB domain of Shc (GST-Shc) associated almost exclusively with pY1148 ( Figure 1c ). Tyr1086 and Tyr1148 are found within the predicted autophosphorylated Asn-Pro-X-Tyr (NPXY in the single-letter amino acid code, where X is any amino acid), so to investigate the contribution of the asparagine and proline residues in target binding, we designed synthetic phosphopeptides in which either of these residues was mutated to alanine. Mutation of either of these residues resulted in abrogation of the interactions, although weak binding to phosphopeptides lacking the proline residues (pY1086 PA and pY1148 PA ) could still be seen in longer exposures of the immunoblot (Figure 1c) . Estimates of the dissociation constants (K d ) between pY1086 and pY1148 phosphopeptides and the soluble PTB domain of Dok-R revealed that the PTB domain could bind to both phosphopeptides with similar relative affinities (Table 1) .
Our results to this point have demonstrated that the PTB domain of Dok-R is required for binding of Dok-R to the phosphorylated EGF receptor in vitro. As Dok-R also contains a PH domain, however, we wanted to examine the contribution of each domain to the association in vivo. We therefore generated a series of mutations in full-length Dok-R that would disrupt the functions of the individual domains, introduced the mutants into COS1 cells and examined their ability to associate with the EGF receptor and undergo tyrosine phosphorylation in response to EGF. Disruption of the PTB domain (PTB*) appeared to have a more dramatic effect on EGF receptor binding and Dok-R phosphorylation than deletion of the PH domain (∆PH), although the disruption of both domains completely abrogated Dok-R phosphorylation (PTB*/∆PH) ( Figure 2 ). Phosphorylation of Dok-R has previously been shown to establish docking sites for downstream SH2-domain-containing signaling proteins including rasGAP and Nck [3] [4] [5] . We found that rasGAP and Nck could associate with Dok-R following EGF stimulation and that phosphorylation at both Tyr276 and Tyr304 was required for rasGAP binding whereas Tyr351 was required for Nck binding (see Supplementary material). These results are in agreement with those recently reported by Lock et al. [6] , who showed that independent tyrosine residues mediate the interactions of rasGAP and Nck with Dok-R.
Recruitment of Dok-R to the EGF receptor and its association with rasGAP suggested that signaling through Dok-R might negatively regulate the Ras-MAP kinase pathway. To test this, we examined the effect of Dok-R expression on activation of the MAP kinase extracellular-signal-regulated kinase 2 (Erk2) by immunoblotting with phosphospecific anti-Erk antibodies and in vitro phosphorylation of the substrate myelin basic protein (MBP). Expression of wild-type Dok-R in COS1 cells resulted in a marked reduction in phosphorylation of Erk2 following EGF stimulation when compared with cells expressing the vector control (Figure 3a) . Interestingly, this suppression of Erk2 activation was not abrogated by the mutant that cannot bind rasGAP (DM; Figure 3a ) or a mutant that cannot bind rasGAP or Nck (data not shown). As expected, the PTB*/∆PH mutant did not reduce Erk2 phosphorylation (data not shown). Table 1 Relative affinities of the PTB domain of Dok-R for phosphopeptides representing EGF receptor Tyr1086 and Tyr1148.
EGF receptor phosphopeptide Binding constant (K d )
Tyr1086 132 nM
The PTB domain of Dok-R binds EGF receptor phosphopeptides with similar relative affinities. Phosphopeptides representing Tyr1086 and Tyr1148 were immobilized on sensor chips and the dissociation constants (K d ) between each of these phosphopeptides and the soluble PTB domain of Dok-R were determined using real-time biosensor (BIAcore) analysis [15] . This analysis provides an estimate of the relative affinity of the PTB domain for each of the two phosphopeptides. These values are likely to be overestimates because of the dimeric nature of GST in these experiments [16] .
The degree of Erk2-mediated phosphorylation of MBP mirrored the observed attenuation of Erk2 phosphorylation ( Figure 3a) . Quantitation of the levels of MBP phosphorylation revealed that, in cells expressing the vector control, phosphorylation of Erk2 was induced within 2 minutes following EGF stimulation and persisted for at least 10 minutes (Figure 3b ). In contrast, in cells expressing wild-type Dok-R, there was 10-fold less induction of Erk2 following 2 minutes of EGF stimulation and the level of activation did not reach vector control levels after 10 minutes of stimulation (Figure 3b) . Interestingly, cells expressing the DM mutant induced Erk2 only marginally more than wild-type Dok-R, suggesting that the association between Dok-R and rasGAP is not required for this attenuation of Erk activity.
As the PTB domain of Dok-R can associate in vitro with the same phosphorylated tyrosine residue on the EGF receptor as Shc, we wanted to confirm that attenuation of Erk activation as a result of Dok-R expression was not due to displacement of Shc from the EGF receptor by Dok-R. We thus isolated Shc from unstimulated or EGF-stimulated COS1 cells that were either untransfected or transfected with Dok-R. Immunoprecipitated Shc isoforms became tyrosine-phosphorylated to the same extent with or without Dok-R; activated EGF receptor and Grb2 were readily detectable in these immunoprecipitates ( Figure 4 ). Tyrosine phosphorylation of Dok-R and the associated EGF receptor could also be observed, and Dok-R did not associate with Grb2 ( Figure 4 ). These experiments demonstrate that Shc signaling complexes are unaffected by the expression of Dok-R and the attenuation of Erk activation by Dok-R was not simply due to a loss of recruitment of the Shc-Grb2 complex to the receptor.
Our findings are consistent with those of Nelms et al. [4] , which demonstrate that overexpression of FRIP in 32D cells inhibits the activation of MAP kinase following interleukin 2 stimulation. As rasGAP negative regulates Ras [13] , the binding of rasGAP to Dok-R is an attractive mechanism Brief Communication 1059
Figure 2
The PTB domain of Dok-R is required for binding to the EGF receptor in vivo and for tyrosine phosphorylation. for suppression of Erk activation by Dok-R. Both Dok and Dok-R can bind rasGAP, but overexpression of Dok has no effect on MAP kinase activation in response to insulin [14] , and a mutant of Dok-R that could not bind rasGAP was unable to rescue Erk activation levels in our studies. These observations suggest that the functional differences in MAP kinase activation between Dok and Dok-R are probably due to unidentified binding partners that are not conserved between the two Dok family members and the physiological consequence of rasGAP binding remains to be determined. The identification of additional Dok-family signaling partners will further illuminate the divergent functions of these docking proteins in growth factor signaling.
Supplementary material
Supplementary material showing the association of Dok-R with rasGAP and Nck and additional methodological details is available at http://current-biology.com/supmat/supmatin.htm. In this report, we have examined the ability of Dok-R to associate with the EGF receptor. In COS1 cells transiently expressing Dok-R, co-immunoprecipitation of Dok-R and EGF receptor and tyrosine phosphorylation of Dok-R could be observed following EGF stimulation ( Figure S1 ). This phosphorylation established docking sites for the SH2-domain-containing signaling proteins rasGAP and Nck ( Figure S2a ). The consensus binding motif for both rasGAP and Nck is Tyr-X-X-Pro (YXXP) [S1-S3] ; this motif is found four times in the Dok-R amino acid sequence at Tyr194, Tyr276, Tyr304 and Tyr351. Synthetic phosphopeptides corresponding to the last three YXXP motifs were generated; the amino-terminal SH2 domain of rasGAP (GAP-N) was found to associate with all three YXXP phosphopeptides in vitro, whereas the SH2 domain of Nck could associate only with phosphopeptides corresponding to Tyr304 and Tyr351 ( Figure S2b) . The presence of a putative Grb2-binding site was also observed in the extreme carboxy-terminal region of Dok-R (Tyr402), but we did not observe any association between the SH2 domain of Grb2 and a phosphopeptide corresponding to this tyrosine ( Figure S2b ).
The tyrosine residues on Dok-R that are phosphorylated in response to growth factor stimulation have not been defined, so the phosphopeptide analysis represented an initial approach to define the binding sites of rasGAP and Nck on Dok-R. To determine which sites could become tyrosine phosphorylated upon EGF stimulation in vivo, we generated HA-tagged tyrosine to phenylalanine point mutations in full-length Dok-R at Tyr276 (Y276F), Tyr304 (Y304F) and Tyr351 (Y351F). We also generated compound mutations in which Tyr276 and Tyr304 were doubly mutated (DM) or all three tyrosine residues were mutated (TM). All mutants were expressed at levels equivalent to wild-type Dok-R in COS1 cells and upon EGF stimulation, all mutants displayed similar levels of tyrosine phosphorylation and association with the EGF receptor ( Figure S2c ). Because the triple mutant appeared to be phosphorylated to the same extent as wild-type Dok-R, it is likely that there are additional sites of tyrosine phosphorylation throughout the protein.
Lysates from these cells were then incubated with immobilized GST-SH2 domains of rasGAP and Nck and bound proteins were visualized by anti-HA immunoblotting.
Both the amino-terminal (GAP-N) and the tandem SH2-SH3-SH2 (GAP-NC) domains of rasGAP associated with all three single point mutants ( Figure S2c ), confirming the peptide data that showed that rasGAP can bind more than one site on Dok-R. The compound double mutant that lacks both Tyr276 and Tyr304 was no longer able to interact with the SH2 domains of rasGAP, however ( Figure S2c ), suggesting that rasGAP associates with Dok-R through a bisphosphorylated target motif comprising Tyr276 and Tyr304. The SH2 domain of Nck could associate with a phosphopeptide representing tyrosine residue 304, but mutation of this site in full-length Dok-R had no effect on Nck binding ( Figure S2c ). In contrast, mutation of Tyr351 in full-length Dok-R completely abrogated binding of Nck to Dok-R ( Figure S2c ), suggesting that Nck interacted with Dok-R exclusively through

Figure S1
Dok-R is a novel substrate of the EGF receptor. Lysates from unstimulated (-) or EGF-stimulated (+) COS1 cells transiently expressing full-length Dok-R were immunoprecipitated (IP) with anti-EGF receptor or anti-Dok-R antibodies and immunoblotted as indicated. Non-immunoprecipitated lysates (lysate) show equal amounts of EGF receptor and Dok-R in the initial lysates. this phosphorylation site. These predictions were confirmed when the compound mutations were analyzed, as the DM mutant was still able to bind Nck but the TM mutant could no longer associate with Nck ( Figure S2c) . In vivo, Nck was coimmunoprecipitated with Y276F, Y304F and DM but not with Y351F or TM ( Figure S2d ). In summary, these results demonstrate that upon EGF stimulation, Tyr276, Tyr304 and Tyr351 of Dok-R are phosphorylated -276 and 304 are required for rasGAP binding and Tyr351 is required for Nck binding.
The SH2 domain of Nck appears to bind exclusively to phosphorylated Tyr351 of Dok-R, which conforms to the predicted YDEP optimal binding motif for Nck [S1] . This tyrosine residue also represents a putative rasGAP-binding site, but the SH2 domains of rasGAP do not appear to bind this site in the context of full-length Dok-R. They associate instead with two different phosphorylated YXXP motifs at Tyr276 and Tyr304. The SH2 domains of rasGAP have been shown to bind simultaneously to two closely spaced phosphotyrosine residues in p190 rhoGAP that are both contained within the motif YXXPXD [S3] . This extended motif is conserved in Dok-R at Tyr276 and Tyr304 and mutagenesis of these closely linked tyrosine residues in Dok-R completely abrogates the interaction between rasGAP and Dok-R. The simultaneous interaction of both SH2 domains with bisphosphorylated targets is thought to promote a conformational change in rasGAP that exposes the target binding surface of the SH3 domain [S3] . We speculate that a similar mechanism occurs upon interaction of rasGAP with Dok-R following EGF stimulation.
Recently, the Nck protein has been shown to exist as Nckα/Nck1 and Nckβ/Nck2 isoforms [S4,S5] . Although neither isoform could interact directly with the EGF receptor, the Nckβ isoform was shown to associate with Dok more strongly than the α isoform [S4] . Furthermore, the β isoform was shown to inhibit EGF-stimulated DNA synthesis in an SH2-domain-dependent manner [S4] . Although we did not determine the identity of the Nck isoform in our immunoprecipitates because of antibody limitations, it is interesting to speculate that the effect of Dok-R expression on Erk activation may in fact be mediated by Nckβ. This notwithstanding, the inability of the mutant that cannot bind rasGAP or Nck to rescue Erk activation levels suggests that additional effector molecules are involved in this downregulation.
Supplementary materials and methods
Plasmids
The cDNA encoding full-length Dok-R [S6] was subcloned into pcDNA3.1(+) (Invitrogen) or pcDNA3.1(+) containing a hemagglutinin (HA) tag (HA-pcDNA3.1; a kind gift of Bryan Snow, AMGEN Institute, Toronto, Canada). Point mutations were introduced using the QuikChange site-directed mutagenesis kit (Stratagene) and all mutations were confirmed by sequencing. To generate Dok-R PTB* and Dok-R GST-PTB*, Arg202 and Arg217 were altered to glutamine. Dok-R ∆PH (amino acids 142-412) was constructed using PCR with appropriate primers containing restriction sites suitable for in-frame insertion into HA-pcDNA3.1. The Dok-R GST-PTB construct was 
Cell culture, transient transfection and binding assays
COS1 cells were maintained and processed as described in [S6] except that cells were serum-starved for 24 h in DMEM containing 0.1% fetal bovine serum (Gibco BRL) before stimulation with 100 ng/ml EGF (Upstate Biotechnology). MBP phosphorylation assays were performed essentially as described in [S7] .
